WO2006122400A1 - Verification method & system for medical treatment - Google Patents
Verification method & system for medical treatment Download PDFInfo
- Publication number
- WO2006122400A1 WO2006122400A1 PCT/CA2006/000781 CA2006000781W WO2006122400A1 WO 2006122400 A1 WO2006122400 A1 WO 2006122400A1 CA 2006000781 W CA2006000781 W CA 2006000781W WO 2006122400 A1 WO2006122400 A1 WO 2006122400A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syringe
- sample
- patient
- blood
- chamber
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000012795 verification Methods 0.000 title abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 179
- 210000004369 blood Anatomy 0.000 claims abstract description 179
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 20
- 230000002123 temporal effect Effects 0.000 claims abstract description 19
- 230000004044 response Effects 0.000 claims abstract description 8
- 239000012530 fluid Substances 0.000 claims description 39
- 230000008878 coupling Effects 0.000 claims description 21
- 238000010168 coupling process Methods 0.000 claims description 21
- 238000005859 coupling reaction Methods 0.000 claims description 21
- 238000004891 communication Methods 0.000 claims description 14
- 238000012545 processing Methods 0.000 claims description 11
- 230000001934 delay Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000012550 audit Methods 0.000 claims description 7
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 6
- 238000012790 confirmation Methods 0.000 claims description 4
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000001360 synchronised effect Effects 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004873 anchoring Methods 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 11
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000007726 management method Methods 0.000 description 15
- 230000036541 health Effects 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 239000007789 gas Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 238000013500 data storage Methods 0.000 description 6
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000013474 audit trail Methods 0.000 description 4
- BWWVXHRLMPBDCK-UHFFFAOYSA-N 1,2,4-trichloro-5-(2,6-dichlorophenyl)benzene Chemical compound C1=C(Cl)C(Cl)=CC(Cl)=C1C1=C(Cl)C=CC=C1Cl BWWVXHRLMPBDCK-UHFFFAOYSA-N 0.000 description 3
- GXVMAQACUOSFJF-UHFFFAOYSA-N 1,3-dichloro-5-(2-chlorophenyl)benzene Chemical compound ClC1=CC(Cl)=CC(C=2C(=CC=CC=2)Cl)=C1 GXVMAQACUOSFJF-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000036647 Medication errors Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011847 diagnostic investigation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150213—Venting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150221—Valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150236—Pistons, i.e. cylindrical bodies that sit inside the syringe barrel, typically with an air tight seal, and slide in the barrel to create a vacuum or to expel blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150244—Rods for actuating or driving the piston, i.e. the cylindrical body that sits inside the syringe barrel, typically with an air tight seal, and slides in the barrel to create a vacuum or to expel blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150305—Packages specially adapted for piercing devices or blood sampling devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/15074—Needle sets comprising wings, e.g. butterfly type, for ease of handling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150763—Details with identification means
- A61B5/150786—Optical identification systems, e.g. bar codes, colour codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150763—Details with identification means
- A61B5/150793—Electrical or magnetic identification means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/417—Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0216—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
Definitions
- the present invention relates to the management of medical treatments. More specifically it relates to a permission-based fluid dispensing device.
- the bar code for human drug products and biological products must contain the National Drug Code (NDC) number in a linear barcode.
- NDC National Drug Code
- the rule is geared toward reducing the number of medication errors in hospitals and other health care settings by allowing health care professionals to use bar code scanning equipment to verify that the right drug (in the right dose and right route of administration) is being given to the right patient at the right time.
- the rule also requires the use of machine-readable information on blood and blood component container labels to help reduce medication errors.
- bar codes require line of sight with a reader in order to be read and they cannot store additional information apart from simple identification data, such as a serial no. or SKU.
- a bar-coded wristband on a patient is not easy to read if the patient gets it wet or is sleeping on top of the arm bearing the wristband, or when the patient is on an emergency room gurney or operating table; these are instances where mistakes in medication or blood transfusion are most prevalent.
- the present invention provides a system for the collection, treatment and delivery of a blood sample, the system comprising: an article for association with a patient having a patient identifier; a first syringe having: a first syringe inlet for drawing an untreated blood sample from the patient, a first fluid chamber for receiving the untreated blood, a first syringe outlet for dispensing the untreated blood sample from the first chamber, a first incremental counter for recording temporal data corresponding to untreated blood events related to the collection of blood, the first syringe being associated with a first unique identifier correlatable to the patient identifier; a vessel for processing the blood sample, the vessel having: a blood sample processing chamber, the vessel having a chamber inlet; the first syringe outlet being operable to establish a dedicated first fluid coupling with the chamber inlet to dispense the untreated blood sample to the blood sample processing chamber; the vessel having a chamber outlet for dispensing
- the present invention provides identification means for identifying an originating patient of the untreated blood sample, verification means for verifying a match between the originating patient and the treated blood sample, and release signal generating means for generating a release signal in response to a positive verification by the verification means.
- the identification means and/or the release signal generating means may be located on the second syringe body, or on an external article.
- the external article may worn, carried, attached or ingested by the patient, such as a pinned or self adhesive label, or a coated object, and the like.
- the external article contains a removable portion containing audit data relating to the patient and/or the treated blood sample.
- the external article may be conveniently provided as a wristband to be worn by the originating patient.
- the second syringe body may also include a filtered vent outlet in the passage for expelling one or more gas constituents in the treated blood sample.
- the present invention provides a method of monitoring a material sample from a patient, comprising the steps of: (a) collecting the sample from the patient with a first collection device; (b) associating the patient with a first signal carrying data representative of the sample; (c) associating the first collection device with a second signal carrying data representative of the sample; (d) delivering the sample to a sample treatment chamber; (e) processing the sample to form a processed sample; (f) collecting the sample in a second collection device; (g) associating the second collection device with a third signal carrying data representative of the processed sample; (h) comparing the data in the first and third signals to link the processed sample with the patient; and thereafter; (i) associating at least one of the steps (a) to (h) with temporal data; (j) determining at least one time delay using the temporal data to determine whether the at least one of the steps (a) to (h) occurs within acceptable time limits; (k) delivering the processed sample to the patient upon
- the events related to the collection of untreated blood are tracked by the first incremental counter, while the treatment and post treatment events are tracked by the second incremental counter, such that time delays may be determined from the temporal data
- these two counters operate independently of one another and do not require to be synchronized with each other, unlike real-time clocks.
- the counters only operate during the steps (a) to Q) described above, and thus do not require substantial battery power.
- the battery is sufficient to maintain substantial accuracy of the clock within the time period from steps (a) to (f), and thus the possibility of losing time or decreasing clock accuracy as the battery's power runs down is substantially eliminated.
- the system includes a releasable lock means operable by a solenoid configured to receive the release signal.
- the system includes a releasable lock means operable by a motorized means configured to receive the release signal.
- treatment device used herein below is intended to mean a device used directly or indirectly in the course of a treatment. It may include devices which actually perform a treatment on the patient or a patient-derived sample, or alternatively be an article for performing functions associated with treatments, such as carrying or otherwise transferring the sample to or from a treatment.
- Figure 1 is a perspective view of a blood treatment system
- Figure 2 is a sectional view of a first syringe shown in Figure 1, taken along line 1-1 '
- Figure 3 is a perspective view of the first syringe of Figure 1 coupled to a sodium citrate bag
- Figure 4 is a perspective view of a blood treatment chamber of Figure 1
- Figure 5 is a perspective view of a second syringe of Figure 1
- Figure 6 is a sectional view of the second syringe of Figure 5 taken along line 5-5'
- Figure 7 is another perspective view of the blood treatment chamber carrying the first syringe and the second syringe
- Figure 8 is a sectional view of
- a system 10 for the collection, treatment and delivery of an autologous blood sample includes a plurality of entities which are used at different stages during the handling of the blood sample, such as, a first syringe 11 (Sl), a sample management unit 12 (SMU), a blood treatment unit 14 (BTU), a second syringe 15 (S2), and a wristband 16 (WB).
- the first syringe 11 is used to collect an untreated blood sample from an originating patient 17.
- the blood collection syringe 1 1 is coupled to the sample management unit with the blood delivery syringe 15 already mounted thereon, and the sample management unit is introduced into the blood treatment unit, in which the untreated blood sample is subjected to one or more stressors, such as ozone or ozone/gas mixture, ultra-violet (UV) light and infra-red (IR) energy.
- stressors such as ozone or ozone/gas mixture, ultra-violet (UV) light and infra-red (IR) energy.
- the treated blood sample is delivered to a second syringe 15, from which the treated blood sample is administered to the originating patient 17.
- the system 10 provides for a verification check, aimed at reducing the possibility of error, and thus ensure that the correct blood sample is returned to the correct originating patient 17.
- the verification check includes the steps of matching the blood sample, either in its treated or untreated form or both, with the originating patient 17.
- the wristband 16, the first syringe 11, the sample management unit 12, the second syringe 15, include identification data associated with the originating patient, the data may include indicia, or may be machine-readable via optical or electro/magnetic means.
- the first syringe 11 has a first body portion 18 which provides a cylindrical cavity 19 which in cooperation with a syringe plunger 20 forms a sample receiving chamber 21.
- the first syringe 11 includes a first channel portion 22 with a channel 23 in communication with the first sample receiving chamber 21, and a first syringe inlet port 24 for ingress of the untreated blood sample from the patient 17.
- the first channel portion 22 also includes a first syringe outlet port 26 for dispensing the untreated blood sample therefrom to the sample management unit 12.
- the first syringe outlet port 26 includes a channel 27 in communication with the first sample receiving chamber 21 and channel 24.
- the first syringe inlet port 24 is provided with a first syringe inlet valve means 28 in channel 24 for controlling the flow of blood through the first syringe inlet 24.
- the first inlet valve means 28 includes a housing 29 containing a valve 30 arranged to be opened by a complementary valve member 31, located on an external device 32, as shown in Figure 3.
- the external device 32 may be a blood collection unit, such as a "butterfly" needle or a sodium citrate bag, and so forth.
- Extending outwardly from the first syringe outlet port 26 is a pair of bayonet pins 72 for coupling the first syringe 11 to the blood treatment chamber 12.
- a valve element 74 biased to a closed position against a valve seat 76 on an end cap 78 which forms the outer end of the first syringe outlet port 26.
- a printed circuit board (PCB) 34 having circuitry for transmitting and receiving data related to the syringe and/or its contents, or a patient 17, such as identification data, SKU, serial no., manufacturing date, expiry date, fluid data, health facility data, health practitioner data, medication data, and so forth.
- the circuitry includes, but is not limited to, a transmitter, a receiver, logic means or processor, a computer readable memory for data storage, a timing circuit, an antenna and a power source.
- the circuitry also includes an RFID reader/writer for reading RFID tags associated with other entities within the treatment system.
- the RFID reader/writer is also coupled to other elements of the circuitry to perform at least one verification check, and other functions.
- input/output devices such as a display, an LED 36, a speaker, and a switch, such as pullout tab 38.
- the first channel portion 22 also includes a cover 40 with a bore 42 contiguous with an opening 44 of the first outlet port 26.
- the first syringe 11 also includes a compartment 46 for housing a power supply unit 48 to provide electrical power to the PCB 34 and the input/output devices.
- the power supply unit 48 typically comprises one or more batteries which may be removed following the single use of the first syringe 11 , in order to enable use in another device or allow for proper recycling in compliance with current environmental regulations. In order to facilitate easy battery installation or removal, the batteries 48 may be placed on a tray which is slidably received by the compartment 46.
- the sample management unit 12 is a vessel 49 having an open top portion 51, a closed bottom portion 56 and a rigid walled portion 58 therebetween, and a cover portion 54 to define a cylindrical treatment cavity 52, or treatment chamber.
- the cover portion 54 has a chamber inlet 50 to form a dedicated first fluid coupling with the first syringe outlet port 26, such that the untreated blood sample may be dispensed into the treatment cavity 52 of the blood sample treatment chamber 12.
- the cover portion 54 also has a gas inlet port 60 for delivery of ozone to treat a blood sample, a gas outlet port 62 for the discharge of the ozone, and other gases.
- the bottom portion 56 has a bowl 66 to receive the blood sample during treatment. [00451
- stressors such as, UV A, B and C radiation, infrared radiation and ozone is bubbled through the blood sample.
- the walled portion 58 and the bowl 66 are made from appropriate materials capable of transmitting such radiation, such as low density polyethylene (LDPE) containing a small amount (about 5%) of ethylene vinyl acetate.
- LDPE low density polyethylene
- the chamber inlet 50 has a female collar portion 68 with a pair of helically oriented passages or grooves 70 extending through its wall, or in its wall, to receive the pair of corresponding bayonet pins 72 of the first syringe outlet port 26.
- the first syringe 11 is rotated to urge the bayonet pins 72 along the helical passages 70 and downwardly into the female collar portion 68 until the valve element 74 abuts the valve-actuating element 80.
- the cover portion 54 has a chamber outlet 81 to form a dedicated second fluid coupling with the second syringe 15, as shown in Figure 8.
- the second syringe 15, shown in more detail in Figure 5 and Figure 6, has a second body portion 82 having a barrel 83 with a proximal end 84, at which is disposed a second inlet port 85, a second outlet port 86; and a distal end 87 with a cylindrical wall 88 therebetween to define a second sample receiving chamber 89.
- the second inlet port 85 is disposed at an angle to the second outlet port 86, and intermediate the second sample receiving chamber 89 and the second outlet port 86.
- a plunger 90 is slidably disposed at the distal end 87 and is in tight fluid engagement with the cylindrical wall 88. The plunger 90 serves to draw fluid into the second sample receiving chamber 89 and urge the fluid therefrom.
- the second syringe 15 also includes a second channel portion 92 with a channel 94 in communication with the second sample receiving chamber 89 and the second outlet port 86, and a channel 96 in communication with the second inlet port 85 and the second sample receiving chamber 89 via a portion of the channel 94.
- a second end cap 91 is removably attached thereto, while the second inlet port 85 includes a slidable cap 98 to prevent contamination prior to use with the blood treatment unit 14.
- the treated blood sample is dispensed from the second syringe 15 to the originating patient 17 via the second syringe outlet port 86 operable between an open position and a closed position by a releasable lock means 100, as will be described below.
- a printed circuit board (PCB) 102 having circuitry for transmitting, receiving and storing data related to the syringe and/or its contents or the originating patient 17, such as identification data, SKU, serial no., manufacturing date, expiry date, fluid data, health facility data, health practitioner data, medication data, and so forth.
- the circuitry includes RFID reader/writer functionality for reading RFID tags associated with other entities within the treatment system.
- the RFID reader/writer is also coupled to other elements of the circuitry to perform at least one verification check, and other functions
- the circuitry includes, but is not limited to, a transmitter, a receiver, logic means or processor, a computer readable medium for data storage, a timing circuit, an antenna and a power source.
- input/output devices such as a display, LED 103, a speaker or a button.
- the PCB 102 also includes circuitry for controlling the operation of the releasable lock means 100.
- a compartment 104 houses a power supply unit 106 comprising one or more batteries, and a power circuit resident on the PCB 102 for regulating the power therein and input/output devices.
- the batteries 106 may be removed after the single use of the second syringe 15, in order to enable use in another device or allow for proper recycling in compliance with current environmental regulations. In order to facilitate easy battery installation or removal, the batteries 106 may be placed on a tray which is slidably received by the battery compartment 104. [0049]
- the syringe 10 is typically maintained in a low power state, when not in use, to conserve battery energy. However, when the sample management unit 12 is introduced into the blood treatment unit, the syringe 15 is placed into an operating state from the lower power state.
- Such a transition may be effected via a mechanical switch which is closed before insertion of the sample management unit into the blood treatment unit, or the switch is closed by the blood treatment unit following insertion of the sample management unit into the blood treatment unit.
- Other ways include an electronic switch actuable by an RF signal or a DC signal from the blood treatment unit, or a DC magnetic reed relay enabled by a magnet in the blood treatment unit.
- the chamber outlet 81 has a female collar portion 108 with a pair of helically oriented passages or grooves 110 extending through or in its wall to engage a corresponding one or more pins 112 extending outwardly from the second syringe inlet port 85.
- a valve element 114 is located in the channel 96 and biased to a closed position against a valve seat 116 on an end cap 118 forming the outer end of the second syringe outlet 96.
- the valve element 114 is also aligned for abutment with a valve actuating element 120 which is positioned in the chamber outlet 81.
- the valve actuating element 120 is thus operable to displace the valve element 114 from its closed position against the valve seat 116 to open the second fluid coupling.
- the cover portion 54 is also provided with a saddle member 122 for supporting the second syringe 15 when it is in a fully engaged position with chamber outlet 81.
- the cover portion 54 has a top cap 124 and a cap lock 126 bonded, welded or otherwise fixed thereto.
- the cap lock 126 latches on an upper periphery of the bottom portion 56.
- the chamber inlet 50 and the chamber outlet 81 are each in fluid communication with the inner treatment cavity 52 by way of conduits 128, 130 extending below the valve actuating elements 80, 120 respectively.
- the second syringe body portion 84 has a cylindrical cavity which in cooperation with the plunger 90 provides a second sample receiving chamber 89.
- the passage 94 of the blood sample transfer portion 92 has a second access location 132 for fluid communication with the second syringe outlet port 86.
- the second syringe outlet port 86 and the blood transfer portion 92 are further provided with the releasable lock means shown generally at 100 for forming a locked third fluid coupling between the second access location 132 and the second syringe outlet port 86.
- the releasable lock means 100 is operable in response to a release signal to release the third fluid coupling, as shown in Figures 13(a) to 13(d). With the releasable lock means unlocked, the second syringe outlet port 86 is operable to form a fourth fluid coupling with a fluid fitting on a common blood sample delivery unit with a complementary LUER 31 or similar fitting, such as the needle 32.
- the second syringe outlet port 86 includes a male Luer insert 134, an outlet valve means generally shown at 136 for opening and closing the access to the fluid channel 92 to control the flow of the blood sample therethrough.
- the male Luer insert 134 includes an opening 138 and a thread for the LUER fitting for coupling with female Luer 31 of a needle 32.
- the outlet valve means 136 includes a valve element portion 140 and a valve seat portion 142 and first actuating means generally shown at 144 for actuating the valve element portion 140 relative to the valve seat portion 142.
- a pair of resilient members 148 such as a spring, biases the outlet valve means 136 in a closed position.
- the first actuating means 144 is operable to displace the valve element portion 140 in different directions when the second syringe body portion 84 is either engaged or disengaged with a female Luer 31.
- the first actuating means 144 takes the form of a plurality of first actuating elements 150 which extend outwardly from a central web 152, and also second actuating means such as a tab 154 extending therefrom.
- the central web 152 is fixed to a block 156 positioned in a channel 94 in the body portion 92 of the second syringe 15.
- the block 156 has a central bore 158 carrying a tubular valve stem 160 having one end carrying the valve element portion 140 and an opposite end carrying a valve stem head 162, which has a peripheral edge region with a sealing element such as an O-ring or the like.
- the valve stem 160 has a pair of fluid transfer holes as shown at 164 immediately beside the valve element portion 140, thereby forming an inner valve passage which is in fluid communication with the second sample receiving chamber 89, as shown in Figures 11 and 12.
- the female Luer 31 includes complementary first actuating elements which displace the first actuating elements 150, when the female Luer 31 member is introduced into the male Luer insert 134.
- the outlet port 86 of the second syringe 15 is operable between three states, a locked state, an open state and permanently locked state, by a releasable lock means, such as locking mechanism 100, as shown in Figures 13(a) to 13(d).
- the locking mechanism 100 includes a pawl 168 coupled to the outlet valve means 136 to control the coupling of the female Luer 31 to the male Luer insert 134 of the second syringe 15.
- the pawl 168 has one end 170 with an opening 172 for receiving a pivoting pin 174, protruding from a board 176, to allow pivoting thereabout.
- the pawl 168 is positioned between a first spring plate 178 and a second spring plate 180 which control its swinging motion.
- the first spring plate 178 is made from fuse material which temporarily changes consistency under the presence of the predetermined electric current signal, such as nickel titanium naval ordinance laboratory intermetallic material (NITINOL).
- NITINOL nickel titanium naval ordinance laboratory intermetallic material
- Nitinol exhibits superelasticity and shape memory, such that nitinol is caused to heat up due to the predetermined electric current signal, as such it is mechanically deformed under stress above a specific temperature, and returns to the pre-stressed position when the stress is removed.
- a first finger 184 and a second finger 186 Adjacent to the recess 188 is a punched out slot 190 which includes a plurality of interconnected slots 192, 194, 196. These interconnected slots 192, 194, 196 correspond to the above-mentioned locked state, the open state and the permanently locked state, respectively.
- the slots 192 and 196 are opposite each other and separated by a pawl tooth 198 on one side of slot 190 and linked to one another by slot 194 on the other side of slot 190.
- the slot 192 is L-shaped and includes one arm 200 and another arm 202 which links to slot 194.
- the first spring plate 178 is secured to the board 176 at one end and includes an arcuate portion 204 positioned above the pawl 168.
- the arcuate portion 204 is bent at approximately 90 degrees at point 208, and adjacent to the point 208 is an abutment flange 210 which engages the arm 200 of slot 192, in the locked position, as shown in Figure 13(a).
- the subsequent positioning of the abutment flange 210 determines the operating state of the syringe 15.
- the motion of the pawl 168 through the three different positions will now be described. Starting in the rest position, the abutment flange 210 is positioned in the arm 200 of slot 192.
- a predetermined electric signal is caused to flow through the first spring plate 178, and the electric signal is sufficient to cause the first spring plate 178 to relax.
- the first spring plate 178 is sufficiently relaxed such that the second spring plate 180 forces the abutment flange 210 out of the arm 200 into arm 202, and finally into slot 194 corresponding to the open position, as shown in Figure 13(b).
- a female Luer 31 of a needle 32 can now be attached to the second syringe 15 and the treated blood is expressed from the second sample receiving chamber 89 via the open outlet valve into the patient 17, as shown in Figure 14.
- the predetermined electric signal is once again caused to flow through the first spring plate 178, and causes the first spring plate 178 to relax.
- the second spring plate 180 forces the abutment flange 210 out of the slot 194 into slot 196 corresponding to the permanently locked position, as shown in Figure 13(c) and 13(d). If the female Luer 31 is still attached when the release signal is issued, then the abutment flange 210 is prevented from sliding into the permanently locked position until the female Luer 31 is removed.
- a predetermined time such as 20 minutes
- the pawl 168 Upon energising the first spring plate 178, the pawl 168 is caused to rotate in a clockwise direction and the abutment flange 210 is forced out of the arm 200 into arm 202, and slides into slot 194 corresponding to the unlocked or open position. Concurrently, the finger 184 of the pawl 168 moves away from the tab 154 such that the tab 154 is now aligned with the recess 188. The female Luer 31 is now be introduced into the male Luer insert 134, and the complementary first actuating elements abut the first actuating elements 150.
- the second syringe 15 includes a de-bubbling system or bubble removal mechanism to expel gas from syringe, before the treated blood sample is administered to the originating patient 17.
- a separate vent cap is attached to the proximal end 84 to interface with the Luer 134.
- the vent cap includes a hydrophobic gas permeable membrane to prevent blood from escaping. Generally, more air can be introduced into the second sample receiving chamber 89 to coalesce the existing bubbles, thus facilitating removal of otherwise small bubbles.
- the barrel 83 is transparent such that a user can inspect the treated blood sample to verify that gas bubbles have been removed.
- the resilient members 148 expand to push the central web 152 towards the opening 138 and the tab 154 travels out of the recess 188 and faces the recess opening 189.
- a predetermined electric signal is caused to flow through the first spring plate 178, and the abutment flange 210 is forced out of the slot 194 into slot 196.
- the tab 154 now abuts the finger 186, and thus any longitudinal displacement of the central web 152 from away from the opening 138 is precluded.
- the system 10 provides a verification protocol which involves number of verification checks to be sure that the proper treated blood sample is delivered to the proper originating patient 17, and that certain events in the collection, treatment and delivery of the blood sample to the patient 17 occurs within prescribed time periods.
- the system has identification means 211 for identifying an originating patient 17, and the untreated blood sample in the first syringe 11, verification means 212 for verifying a match between the originating patient 17 and the treated blood sample in second syringe 15, and release signal generating means 214 for generating a release signal in response to a positive outcome by the verification means.
- the release signal is transmitted to the releasable lock means 100 to deliver the predetermined current to the first spring plate 178, thereby to render the second syringe 15 operable to deliver the treated blood sample to the originating patient 17.
- the identification means 211 and the release signal generating means 214 are located on the second syringe 15, but may be located in the aforementioned entities.
- the releasable lock means 100 has a signal receiving means 216 for receiving the release signal.
- the verification means 212 includes comparison means 218 for comparing patient identity data with treated blood sample identity data, both stored in memory means 220, and signal receiving means 216 to receive one or more signals associated with the originating patient identity data and/or the blood sample identity data (either untreated, treated or both). In this case, the one or more signals contain the originating patient identity data and/or the blood sample identity data.
- the one or more signals may contain data which is associated with or related to the patient 17 or blood sample identity data.
- the data in the signals may include one or more codes which allow the patient identity data or the blood sample identify data to be obtained from a data structure in the memory means 220 or some other location, for example in the form of a look up table, for instance [0068]
- the verification means 212 also includes a counter means 221 which provides temporal data related to a predetermined event including and/or between an untreated blood sample collection event and a treated blood sample delivery event.
- the temporal data may also include at least one elapsed time value between two predetermined events including or between the untreated blood sample collection event and the treated blood sample delivery event.
- the counter means 221 may be implemented as a first incremental counter 222 on first syringe 11 and a second incremental counter 224 on the second syringe 15 are used to track time delay.
- the first incremental counter 222 tracks the events related to the collection of untreated blood, while the treatment and post treatment events are tracked by the second incremental counter 224.
- These two incremental counters 222 and 224 operate independently of one another and do not require to be synchronized with each other.
- the battery power is sufficient to maintain substantial accuracy of their internal clock within the time period from collection of the untreated blood sample to the delivery of the treated blood sample to the patient 17. Therefore, the possibility of losing time or decreasing clock accuracy as the battery's power runs down is substantially eliminated.
- the verification means 212 may be operable to prevent release of the locked third fluid coupling when the elapsed time value has exceeded a predetermined value. Before treatment of the untreated blood sample, the verification means 212 is also operable to prevent treatment of the blood sample when the elapsed time value has exceeded a predetermined value. Similarly, following treatment, the verification means 212 is operable to verify a match between the untreated blood sample in the first syringe 1 1 and the originating patient 17. [0070J
- the verification protocol may be implemented in a number of forms, although the most preferred at present is by the use of one or more radio frequency signal transmitters and receivers and RFID tags.
- the wristband 16 is provided with a passive RFID tag, such as WB RFID tag 226, while the first syringe 11 and the second syringe 15 include the aforementioned printed circuit board (PCB) 102 having circuitry for transmitting, receiving and storing data related to the syringe and/or its contents or the originating patient 17, including a Sl RFID reader/writer 228 and a S2 RFID reader/writer 230, respectively.
- the passive WB RFID tag 226 comprises an antenna coil and a silicon chip that includes modulation circuitry and non-volatile memory.
- the passive WB RFID tag 226 is energized by an external time-varying electromagnetic radio frequency (RF) wave that is transmitted by a RFID reader/writer, such as the Sl RFID reader/writer 228 or the S2 RFID reader/writer 230. Therefore, Sl RFID reader/writer 228 or the S2 RFID reader/writer 230 is capable of writing data onto the WB RFID tag 226, and reading data back from WB RFID tag 226 by detecting the backscatter modulation.
- the blood treatment unit 14 is also equipped with a BTU RFID reader/writer 232 to receive a pre-treatment identity data from the Sl RFID reader/writer 228 and to receive post treatment data from the S2 RFID reader/writer 230.
- the blood treatment chamber 12 is equipped with a passive SMU RFID tag 234 to provide an identification code.
- the BTU RFID reader/writer 232 issues query signals to the SMU RFID tag 234 to determine whether the blood treatment chamber 12 is valid for use in the treatment process, that is, whether the blood treatment chamber 12 is an authentic product or whether it has been previously used.
- the wristband 16 contains a removable portion 236 containing the WB RFID tag 226 and audit data written onto it relating to the patient 17 and/or the treated blood sample.
- the wristband 16 may also include a buckle assembly 238 having a base portion 240 and cover portion 241.
- the base portion 240 is integrally formed with a band 242 of resilient material which a number of perforations forming passages 244 to receive the buckle assembly 238.
- the base portion 240 has pins 246, 247, 248 that are dimensioned to fit through the passages 244.
- the cover portion 242 is hinged to the base portion 240 by way of a hinge shown at 250.
- the cover portion 242 also has a pair of cavities 252, each for receiving one of the pins 246 or 248.
- the pin 247 may press against a switch (not shown) in the base portion 240 to activate portions of the circuitry of the wristband 16, upon securement of the band 242 around the patient's 17 arm.
- the verification protocol makes use of a number of identification codes, such as a first syringe identity code representative of the untreated blood sample therein, and the a wristband identity code representative of the originating patient 17.
- the first syringe identity code and the wristband identity code may include common identity data, though the data between them may be different or related as the case may be.
- the first syringe identity code may, if desired, include a first time value representative of the time of untreated sample collection from the originating patient 17 (or a designated event either before or after the sample collection step) and/or verification thereof.
- the S 1 RFID reader/writer 228 functions as a first signal emitter for emitting a first signal carrying the first syringe identification code data, and/or common identity data, while the WB RFID tag 226 on the wristband 16 functions as a first signal receiver to receive the first signal.
- the second syringe 15 is assigned a second syringe identity code, which is representative of the treated blood sample therein.
- the second syringe identity code includes a second time value representative of the time of the treated sample delivery thereto from the treatment cavity 52 (or a designated event either before or after the treated sample delivery step) and/or verification thereof.
- the S2 RFID reader/writer 230 functions as a second signal emitter for emitting a second signal carrying the treated blood sample identity data and the WB RFID tag 226 functions as a second signal receiver means to receive the second signal, wherein the verification means 212 is operable to compare the first signal data with data representative of the treated blood sample.
- the verification protocol will now be discussed along with a typical blood treatment procedure. As shown in Figure 1, a kit for a blood treatment procedure is assembled including, among other things, the wristband 16, the first syringe 11, the second syringe 15, the sample management unit 12 and a number of prepared labels 258 with patient identification printed thereon.
- the procedure starts with the activation of the first syringe 11 via an actuating means such as the pullout tab button 38.
- the circuitry on PCB 34 is powered on by the batteries 48 and conducts a power-on-self-test (POST) procedure and subsequently the first syringe 11 is ready for use, barring any detected faults during the POST procedure.
- POST power-on-self-test
- the Sl RFID reader/writer 228 is then activated and starts transmitting query signals and waits for an acknowledgement response from the passive WB RFID tag 226.
- the first incremental counter 222 is also initiated and outputs temporal data, and keeps track of the untreated blood events and log time stamps associated with predefined untreated blood events, in association with the logic means.
- a timestamp TSO indicative of the event of power- on is recorded by the second incremental counter 224 and stored in memory.
- the Sl RFID reader/writer 228 and the WB RFID tag 226 each contain common patient identity data or sample treatment data, coded as ID 1.
- a blood anti- coagulant such as sodium citrate solution, is also drawn into the first sample receiving chamber 21 to prevent clotting of the blood, as shown in Figure 3.
- a sample of blood is then withdrawn from the patient 17, and once primed, the first syringe 11 is brought to within RF range of the wristband 16.
- the Sl RFID reader/writer 228 queries the WB RFID tag 226 to verify that the data read from or emitted by the WB RFID tag 226 corresponds to the common patient identity data IDl on Sl RFID reader/writer 228. The process is terminated if there is no correlation between the data on the wristband 16 and the first syringe 11.
- the Sl RFID reader/writer 228 records a "time data stamp" TSl stamp on the Sl RFID reader/writer 228, and writes the same time-stamp to the WB RFID tag 226, Therefore the Sl RFID reader/writer 228 and the WB RFID tag 226 now carry TSO, TS l and IDl .
- the data now on the Sl RFID reader/writer 228 and the WB RFID tag 226, may be represented as: Sl IDl TSO TSl meaning that the untreated blood sample drawn into the first syringe 11 is from a patient with the identification IDl, the first syringe 11 was powered on at time TSO, and the common patient identity data IDl on the first syringe 11 and the wristband 16 was matched at time TS 1.
- the first syringe 11 logic means receives temporal data from the first incremental counter 222 and determines the elapsed time from the start of the procedure (TSO) and the instant that the common patient identity data IDl on the first syringe 11 and the wristband 16 is matched, The process advances as long as the time unit difference between TSO and TSl is within an acceptable predefined range.
- the first syringe 11 is installed on the blood treatment chamber 12 (with the second syringe 15 already positioned thereon), which is then delivered to the blood treatment unit 14.
- the Sl RFID reader/writer 228 emits the data TSO, TSl, IDl to the BTU RFID reader/writer 232.
- the data also include a time value TS2 denoting a treatment start time.
- the blood treatment unit 14 then calculates the time delay between TSl and TS2 of the first springe 11.
- the blood treatment unit 14 issues a query signal to the SMU RFID tag 234 on the sample management unit 12 and, in response thereto, the SMU RFID tag 234 issues a signal containing its identification code to the blood treatment unit 14.
- This identification code includes an "enable” code indicating that the blood treatment chamber 12 has not been previously used for a blood treatment, thus reducing the risk of contamination the current untreated blood sample SI.
- the SMU RFID tag 234 need not issue an enable code, but rather merely emit a signal containing identity data such as a SKU or the like.
- a SMU RFID tag 234 on the blood treatment chamber 12 receives a disable code from the BTU 14 after the blood sample is delivered to it, thereby preventing the reuse of the blood treatment chamber 12.
- the SMU RFID tag 234 may be disabled in other ways without writing a disable code thereon.
- the SMU RFID tag 234 may be rendered inoperable by issuing the SMU RFID tag 234 a signal causing a fuse to be blown therein.
- the second syringe 15 is powered on and starts querying the BTU RFID reader/writer 232 for data.
- a new time stamp signifying the end of the blood sample treatment "TS3" is written to the BTU RFID reader/writer 232, and subsequently TS3 is read by the S2 RFID reader/writer 230, and stored thereon.
- the treated blood is then delivered from the treatment cavity 52 via the conduit 130 and to the second syringe 15, and.
- the blood treatment unit 14 may also include the TSl stamp, meaning that the data written to the S2 RFID reader/writer 230 would include IDl, TSO, TSl, TS2, and TS3.
- the second syringe 15 includes the treatment start time TS2 and the treatment end time TS3.
- TS2 or TS3 may include a treatment duration time, or some other code indicating that all previous verification steps have been successfully carried out.
- the blood treatment unit 14 may record the following data: Sl ID l TSO TSl PATIENT ID TREATMENT START TS2 TREATMENT END TS 3 Sl IDl TSO TSl TS3
- the PATIENT ID code may include other patient-related data that is manually or automatically entered into the blood treatment unit 14.
- the patient- related data is transferred to the blood treatment unit 14 from a central data storage centre, a server computer, a memory bank or the like.
- the second syringe 15 is then transported back to the originating patient 17 wearing the wristband 16 and the S2 RFID reader/writer 230 continually polls the WB RFID tag 226 until the latter is within range of the query signals. In response to the query signals, the WB RFID tag 226 then emits IDl data, at time "TS4". The S2 RFID reader/writer 230 then calculates the time delay between TS3 data and the time of arrival, TS4, of the second syringe 15 back to the wristband 16. If the expected time delay is exceeded, then the second syringe 15 remains locked by the locking mechanism 100, otherwise the process continues. [OO8f5] The second syringe 15 records IDl, and the time stamp "TS4".
- the second syringe 15 may include the PATIENT ID data as well as the IDl, TSl, TS2, TS3. This data is subsequently written onto the WB RFID 226.
- the S2 RFID reader/writer 230 issues a release signal to the locking mechanism 100 to unlock the second syringe 15, by issuing a predetermined current to the spring plate 178 to force the abutment flange into slot 194, thereby rendering the second syringe 15 operable for injection.
- the WB RFID tag 226 therefore records: Sl IDI TSO TSl S2 15 IDl TSO TSl TS2 SAMI 1 LE MATCH TS3 S2 UNLOCK TS4 [0087]
- the verification protocol is then completed when the TS4 is recorded in the WB RFID tag 226 after it performs a sample match between the IDl data on the S2 RFID reader/writer 230 and the WB RFID tag 226.
- the removable portion 236 of the wristband 16 is then separated therefrom and matched with the originating patient's record and the patient record is returned to the blood treatment unit 14 for a data exchange between the WB KFID tag 226 and the blood treatment unit 14, to complete the audit trail.
- an RF reading audit record capture station may be provided which is local to the patient 17 or to a patient record area in a medical facility, thereby eliminating the need for the patient record to be returned to the blood treatment unit 14.
- the audit record capture station may be capable of downloading the patient record to complete the audit trail.
- the RF reading audit record capture station may be part of the internal network of the medical facility, either through a wired or wireless data port, or may be part of a network localized to one or more blood treatment unit systems in the medical facility. It may collect data and allow for later batch recording to a computer readable medium, such as an optical disc, hard drive or other storage device. It may be attached to or integrally formed with a computing device, personal digital assistant, a mobile phone or the like.
- the data IDl and TS4 is delivered to blood treatment unit 14 or other system to complete the audit trail.
- the time stamp may also include an "event" code, which may comprise five major events: [0090] 1) Sl start time 2) WB acknowledges with Sl 3) Start of Treatment 4) End of Treatment 5) Match between the Treated Sample and the Originating Patient.
- the time stamp may also include any one or more of a number of Error events 1) No match 2) Sl does not match with WB at before/after collection 3) S2 does not match with WB on return after Treatment. 4) Time Delay- exceed time to collect of blood 5) Time Delay- exceed time to deliver sample to BTU 6) Time Delay- exceeds time to return to patient.
- the TS3 time stamp may also include a "match" code as follows: 01 Match 02 No match [0091]
- the wristband includes electronic circuitry coupled to the passive WB RFID tag 226, and a battery for providing power to the electronic circuitry.
- the wristband 16 includes outputs means, such as LEDs 260, 262, 264, or a speaker (not shown), which are operated in different combinations of one or more thereof.
- the LEDs 260, 262 may be operable to illuminate in accordance to a predetermined cycle indicative of the communication associated with verification process with the first syringe 11 and the second syringe 15.
- the third LED 264 may be provided for alarm situations.
- the wristband includes electronics circuitry coupled to the passive WB RFID tag 226, and a battery for providing power to the electronic circuitry.
- the wristband 16 includes outputs means, such as LEDs 260, 262, 264, or a speaker (not shown), which are operated in different combinations of one or more thereof.
- the LEDs 260, 262 may be operable to illuminate in accordance to a predetermined cycle indicative of the communication associated with verification process with the first syringe 1 1 and the second syringe 15.
- the third LED 264 may be provided for alarm situations.
- the wristband 16 may be replaced by some other article to be worn, carried, attached or ingested by the patient 17, such as a pinned or self adhesive label 258 and the like.
- the second syringe 15 may also include a second sample receiving chamber 89 volume detector to determine whether the received treated blood from the treatment cavity 52 is within a predefined range suitable for injection into the patient 17 to provide the desired medical treatment.
- the system 10 includes a blood sample treatment chamber, similar to the sample blood treatment chamber 12 of Figure 4, with an expandable treatment cavity 52 formed by a cover portion 54, a bottom portion 56 and a flexible walled portion 58 therebetween.
- the system includes a locking mechanism 100 operable by a solenoid or motorized means configured to receive the release signal.
- the system includes a wristband 16 with electronic circuitry for transmitting, receiving and storing data related the originating patient 17, such as identification data or an identifier, SKU, serial no., manufacturing date, expiry date, health facility data, health practitioner data, medication data, and so forth.
- the circuitry includes, but is not limited to, a transmitter, a receiver, logic means or processor, a computer readable memory for data storage, a timing ' circuit, an antenna and a power source.
- the circuitry also includes an RFID reader/writer for reading RFID tags associated with other entities within the treatment system, such as the first syringe 11, the second syringe 15, or the sample management unit 12.
- a wristband tag is not limited to, a transmitter, a receiver, logic means or processor, a computer readable memory for data storage, a timing ' circuit, an antenna and a power source.
- the circuitry also includes an RFID reader/writer for reading RFID tags associated with other entities within the treatment system, such as the first syringe 11, the second s
- This wristband 16 acts as the archive data storage for the entire treatment and therefore provides the audit trail once the treatment has been completed.
- the data may be stored in the computer readable medium, such as RAM, ROM, flash memory, and so forth, or the wristband may include an RFID tag to which the data is written.
- the first syringe 11 and the second syringe 15 include a printed circuit board (PCB) having circuitry for transmitting, receiving and storing data related to the syringe and/or its contents or the originating patient 17, such as identification data or identifiers, SKU, serial no., manufacturing date, expiry date, fluid data, health facility data, health practitioner data, medication data, and so forth.
- PCB printed circuit board
- the circuitry is implemented as an active RFID tag having a transmitter, a receiver, logic means or processor, a computer readable medium for data storage, a timing circuit, an antenna and a power source such as a batteries. Also coupled to the PCB are input/output devices such as a display, LED, a speaker or a button.
- the second syringe 15 also includes circuitry for controlling the operation of a releasabie lock means or electromechanical interlock to prevent re-injection of treated blood in the event that the wristband 16 identifier and second syringe identifiers do not match.
- the system includes a BTU reader/writer which can communicate (read and write) to RFID tags of the first syringe 11 and the second syringe 15 and to a tag on the sample management unit 12.
- the first syringe 11 RFID tag stores and record data relating to the patient for example, the time blood was removed for treatment. It will also ensure that the syringe 1 1 cannot be re-used.
- the first syringe 11 RFID tag will also include an elapsed time counter and a matching identifier to that contained in the wristband written at the time of manufacture or packaging.
- the second syringe 15 RFID tag includes similar functions and includes logic and circuitry to drive an electromechanical interlock.
- the flow of treatment events are similar to the one described above. Prior to removal of blood, a check is performed to verify that the unique treatment set ID numbers contained in the wristband 16 and in the first syringe 11 match, by having the syringe 1 1 active tag emit the data to the wristband 16 reader/writer. If there is a match, this event is recorded by the wristband and blood is withdrawn from the patient. At the same time the elapsed time counters in the syringe 11 tag and wristband 16 will start. [00102] The first syringe 11 is then be fitted onto the sample management unit (SMU) 12, which is already fitted with a single-use second syringe 15.
- SMU sample management unit
- the SMU 12 with both syringes 1 1,15 is then taken to the blood treatment unit (BTU) 14 with a BTU reader/writer.
- the patient details are entered into the BTU reader at this stage.
- the blood treatment unit 12 reader/writer will read the first syringe 11 tag and write the details (including the unique ID) to the second syringe 11 tag.
- the BTU reader/writer will also write a message to the SMU tag to indicate it has been used.
- the BTU reader/writer will read the elapsed time from the first syringe 11 tag and calculate treatment time details. These are then written to the second syringe 11 tag along with patient ID.
- the BTU reader/writer writes the completed treatment time to the second syringe 15 tag.
- the SMU 12 is removed from BTU.
- S2 syringe is removed from the SMU 12, and the SMU 12 and Sl syringe are discarded.
- the second syringe 15 is then presented to the wristband 12 on the patient and, provided the unique IDs match and elapsed time is within set parameters, the second syringe 15 locking mechanism is released and the second syringe 15 can be used to inject the treated blood into the patient.
- the wristband 12 reader/writer writes the patient data and procedure details to the wristband 12 tag or computer readable medium, for subsequent removal for storage with patient records.
- the wristband 12 reader/writer is then deactivated and its strap is cut to allow removal from the patient and disposal.
- a network RFID reader is used to read the encrypted data in the wristband tag memory unit or computer readable medium for transfer to the health facility database on a computer or network.
- the BTU reader/writer or an external reader/writer provides all the verification checks [00105] Even though the description above is in large part focused on the use of system 10 in the treatment of autologous blood samples, it will be understood that the system 10, its components and alternatives thereof, may be used for samples other than blood samples, such as bone marrow or, lymphatic fluids, semen, ova- fluid mixtures, other bodily fluids or other medical fluids which may or may not be "autologous", for example fluid mixtures perhaps containing a patient's desired solid sample such as from organs, body cells and cell tissue, skin cells and skin samples, spinal cords.
- the system 10 may also be used for medical testing where it is important to ensure that test results of a particular test can be delivered to the originating patient 17.
- syringes 11 and 15 it will be understood that other devices may be used such as, alone or in combination, one or more syringes, IV bottles, powder and/or atomized fluids and/or gas inhalant dispensers, implant delivery dispensers, ventilators, syringe pumps, intubation tubes, gastrointestinal feeding tubes, or a plurality and/or a combination thereof.
- One of the treatment devices may also comprise a blood treatment device such as that disclosed in International Publication No.
- WO0119318A1 entitled "APPARATUS AND PROCESS FOR CONDITIONING MAMMALIAN BLOOD” (the entire contents of which are incorporated herein by reference).
- one treatment device may be equipped to perform a range of invasive and non-invasive treatments such as surgeries, treatments for diseases such as cancer, as well as exploratory or diagnostic investigations such as X-rays, CAT Scans, MRFs and the like.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008511513A JP2008539991A (en) | 2005-05-19 | 2006-05-15 | Medical procedure confirmation method and confirmation system |
BRPI0611364-8A BRPI0611364A2 (en) | 2005-05-19 | 2006-05-15 | blood sample collection, treatment and administration system, coverage and method for monitoring a patient's material sample |
MX2007014407A MX2007014407A (en) | 2005-05-19 | 2006-05-15 | Verification method & system for medical treatment. |
CA002605675A CA2605675A1 (en) | 2005-05-19 | 2006-05-15 | Verification method & system for medical treatment |
AU2006246927A AU2006246927A1 (en) | 2005-05-19 | 2006-05-15 | Verification method & system for medical treatment |
EP06741496A EP1898974A1 (en) | 2005-05-19 | 2006-05-15 | Verification method&system for medical treatment |
IL186558A IL186558A0 (en) | 2005-05-19 | 2007-10-10 | Verification method & system for medical treatment |
NO20075879A NO20075879L (en) | 2005-05-19 | 2007-11-15 | Procedure and system for verification of medical treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68296905P | 2005-05-19 | 2005-05-19 | |
US60/682,969 | 2005-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006122400A1 true WO2006122400A1 (en) | 2006-11-23 |
Family
ID=37430882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2006/000781 WO2006122400A1 (en) | 2005-05-19 | 2006-05-15 | Verification method & system for medical treatment |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1898974A1 (en) |
JP (1) | JP2008539991A (en) |
KR (1) | KR20080009208A (en) |
CN (1) | CN101208120A (en) |
AU (1) | AU2006246927A1 (en) |
BR (1) | BRPI0611364A2 (en) |
CA (1) | CA2605675A1 (en) |
IL (1) | IL186558A0 (en) |
MX (1) | MX2007014407A (en) |
NO (1) | NO20075879L (en) |
RU (1) | RU2007146837A (en) |
WO (1) | WO2006122400A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017093838A1 (en) * | 2015-12-03 | 2017-06-08 | Lacerta Technologies Inc. | Method and apparatus for preparing blood fraction concentrate |
CN109640638A (en) * | 2016-03-31 | 2019-04-16 | 思恩培绍特信托有限公司 | Device and method for sampling |
US10974038B2 (en) | 2014-03-14 | 2021-04-13 | Fresenius Medical Care Deutschland Gmbh | Medical functional device with a valve seat for a remanent check valve |
US11013847B2 (en) | 2009-04-23 | 2021-05-25 | Fresenius Medical Care Deutschland Gmbh | External functional means, blood treatment apparatus for receiving an external functional means in accordance with the invention, and method |
EP3909542A3 (en) * | 2020-05-12 | 2021-12-08 | Covidien LP | Surgical systems and methods for protecting against unauthorized use |
US11458234B2 (en) | 2014-03-14 | 2022-10-04 | Fresenius Medical Care Deutschland Gmbh | Fluid cassette with alignment latching having an improved tilt-tolerance as well as a blood treatment apparatus |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011008856A1 (en) * | 2011-01-18 | 2012-07-19 | Fresenius Medical Care Deutschland Gmbh | Method for carrying out a query of a specification feature of a medical-technical functional device, medical-technical functional device, medical-technical treatment device and control device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876926A (en) * | 1996-07-23 | 1999-03-02 | Beecham; James E. | Method, apparatus and system for verification of human medical data |
US20030004751A1 (en) * | 2001-05-24 | 2003-01-02 | Kok-Hwee Ng | System and method for tracking a blood collection kit in a blood collection facility |
EP1543852A1 (en) * | 2002-07-18 | 2005-06-22 | Nikkiso Company Limited | Blood treating apparatus and blood treating method |
-
2006
- 2006-05-15 AU AU2006246927A patent/AU2006246927A1/en not_active Abandoned
- 2006-05-15 KR KR1020077026644A patent/KR20080009208A/en not_active Application Discontinuation
- 2006-05-15 CA CA002605675A patent/CA2605675A1/en not_active Abandoned
- 2006-05-15 CN CNA2006800159581A patent/CN101208120A/en active Pending
- 2006-05-15 BR BRPI0611364-8A patent/BRPI0611364A2/en not_active Application Discontinuation
- 2006-05-15 WO PCT/CA2006/000781 patent/WO2006122400A1/en active Application Filing
- 2006-05-15 EP EP06741496A patent/EP1898974A1/en not_active Withdrawn
- 2006-05-15 MX MX2007014407A patent/MX2007014407A/en not_active Application Discontinuation
- 2006-05-15 RU RU2007146837/14A patent/RU2007146837A/en not_active Application Discontinuation
- 2006-05-15 JP JP2008511513A patent/JP2008539991A/en active Pending
-
2007
- 2007-10-10 IL IL186558A patent/IL186558A0/en unknown
- 2007-11-15 NO NO20075879A patent/NO20075879L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876926A (en) * | 1996-07-23 | 1999-03-02 | Beecham; James E. | Method, apparatus and system for verification of human medical data |
US20030004751A1 (en) * | 2001-05-24 | 2003-01-02 | Kok-Hwee Ng | System and method for tracking a blood collection kit in a blood collection facility |
EP1543852A1 (en) * | 2002-07-18 | 2005-06-22 | Nikkiso Company Limited | Blood treating apparatus and blood treating method |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11013847B2 (en) | 2009-04-23 | 2021-05-25 | Fresenius Medical Care Deutschland Gmbh | External functional means, blood treatment apparatus for receiving an external functional means in accordance with the invention, and method |
US10974038B2 (en) | 2014-03-14 | 2021-04-13 | Fresenius Medical Care Deutschland Gmbh | Medical functional device with a valve seat for a remanent check valve |
US11458234B2 (en) | 2014-03-14 | 2022-10-04 | Fresenius Medical Care Deutschland Gmbh | Fluid cassette with alignment latching having an improved tilt-tolerance as well as a blood treatment apparatus |
WO2017093838A1 (en) * | 2015-12-03 | 2017-06-08 | Lacerta Technologies Inc. | Method and apparatus for preparing blood fraction concentrate |
CN109640638A (en) * | 2016-03-31 | 2019-04-16 | 思恩培绍特信托有限公司 | Device and method for sampling |
US20220022418A1 (en) * | 2016-03-31 | 2022-01-27 | Snpshot Trustee Limited | Apparatus and methods for sampling |
US11382308B2 (en) | 2016-03-31 | 2022-07-12 | Snpshot Trustee Limited | Apparatus and methods for sampling |
EP3909542A3 (en) * | 2020-05-12 | 2021-12-08 | Covidien LP | Surgical systems and methods for protecting against unauthorized use |
Also Published As
Publication number | Publication date |
---|---|
EP1898974A1 (en) | 2008-03-19 |
CA2605675A1 (en) | 2006-11-23 |
NO20075879L (en) | 2008-02-15 |
RU2007146837A (en) | 2009-06-27 |
IL186558A0 (en) | 2008-01-20 |
JP2008539991A (en) | 2008-11-20 |
MX2007014407A (en) | 2008-04-22 |
CN101208120A (en) | 2008-06-25 |
BRPI0611364A2 (en) | 2010-08-31 |
AU2006246927A1 (en) | 2006-11-23 |
KR20080009208A (en) | 2008-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060264778A1 (en) | Verification method and system for medical treatment | |
US20070179453A1 (en) | Material dispenser with a control valve | |
US20060270997A1 (en) | Permission-based material dispenser | |
CN205658923U (en) | System for be used for pouring into medicament into to patient | |
US20050154368A1 (en) | Medical material handling systems | |
WO2006122400A1 (en) | Verification method & system for medical treatment | |
US7216802B1 (en) | Method and apparatus for verifying information | |
AU2004286716B2 (en) | Drug delivery pen with event notification means | |
US7236936B2 (en) | Security infusion pump with bar code reader | |
EP2037999B1 (en) | Smart parenteral administration system | |
JP2023052698A (en) | Injection monitoring device | |
US20070225653A1 (en) | Material dispenser with a solenoid lock | |
JP2006524069A (en) | Discharge device | |
WO2009087374A1 (en) | Locking system for blood bags | |
WO2020214717A1 (en) | System for onboard electronic encoding of the contents and administration parameters of iv containers and the secure use and disposal thereof | |
US20100065633A1 (en) | Electronic tag system | |
JP2008545463A (en) | Sample management unit | |
ZA200604821B (en) | Medical material handling systems | |
US20230130432A1 (en) | Medical intravenous fluid delivery and disposal devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006246927 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 562218 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 186558 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2605675 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006246927 Country of ref document: AU Date of ref document: 20060515 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006246927 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8612/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680015958.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077026644 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008511513 Country of ref document: JP Ref document number: MX/a/2007/014407 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006741496 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007146837 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006741496 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0611364 Country of ref document: BR Kind code of ref document: A2 |